<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016873</url>
  </required_header>
  <id_info>
    <org_study_id>CLH002</org_study_id>
    <nct_id>NCT01016873</nct_id>
  </id_info>
  <brief_title>INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD</brief_title>
  <acronym>INTREPID</acronym>
  <official_title>A Double-masked, Sham Controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oraya Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oraya Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and establish the effectiveness of two
      doses from the IRay System for the treatment of wet AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to confirm the safety of low voltage external beam radiotherapy
      using the IRay System at two dose levels for the treatment of CNV secondary to neovascular
      AMD and to determine if the IRay System is effective in sparing the number of Lucentis
      injections during the first 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Lucentis® Injections Up To And Including Week 52</measure>
    <time_frame>During the first 52 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Visual Acuity (VA)</measure>
    <time_frame>Weeks 12, 28, 52 and 104.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (Pct.) of Patients (Pts.) Losing &lt; 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</measure>
    <time_frame>Weeks 12, 28 and 52.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (Pct.) of Patients (Pts.) Gaining ≥ 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</measure>
    <time_frame>Weeks 12, 28 and 52.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (Pct.) of Patients (Pts.) Gaining ≥ 0 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</measure>
    <time_frame>Weeks 12, 28 and 52.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Mandatory Injection at Day 0 to the First PRN Injection.</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number (No.) of Lucentis® Injections (Inject.) During The First 12, 28, and 104 Weeks.</measure>
    <time_frame>Week 12, 28, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Choroidal Neovascularization (CNV) as % of Lesion on Fluorescein Angiography (FA) From Baseline to Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>AMD</condition>
  <condition>Wet AMD</condition>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Wet Age-Related Macular Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <condition>Eye Diseases</condition>
  <condition>Retinal Diseases</condition>
  <arm_group>
    <arm_group_label>16 Gy IRay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 Gy IRay + PRN Lucentis®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham 16 Gy IRay</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham 16 Gy IRay + PRN Lucentis®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 Gy IRay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 Gy IRay + PRN Lucentis®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham 24 Gy IRay</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham 24 Gy IRay + PRN Lucentis®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IRay</intervention_name>
    <description>Low voltage stereotactic radiotherapy system</description>
    <arm_group_label>16 Gy IRay</arm_group_label>
    <arm_group_label>Sham 16 Gy IRay</arm_group_label>
    <arm_group_label>24 Gy IRay</arm_group_label>
    <arm_group_label>Sham 24 Gy IRay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have neovascular AMD diagnosed within the previous 3 years, have
             received at least 3 injections with Lucentis® or Avastin® within the previous year and
             have the need for treatment with anti-VEGF therapy due to increased fluid or
             persistent cysts on OCT, or leakage on FA.

          -  Patients must have a total lesion size of &lt;12 disc areas and a CNV lesion with the
             greatest linear dimension of &lt;6 mm, but not greater than 3 mm from the center of the
             fovea to the furthest point on the lesion perimeter.

          -  The distance from the center of the fovea to the nearest edge of the optic disc should
             be not less than 3 mm.

          -  Patients must Patient must be at least 50 years of age.

          -  Women must be post-menopausal ≥1 year or surgically sterilized, or a pregnancy screen
             must be performed prior to the study and a reliable form of contraception approved by
             the investigator must be maintained during the study.

          -  Patient must have best corrected visual acuity of 75 to 25 letters in the study eye
             and at least 20 letters in the fellow eye.

        Exclusion Criteria:

          -  CNV due to causes other than AMD, including ocular histoplasmosis syndrome, angioid
             streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia (spherical
             equivalent ≥ -8 diopters).

          -  An axial length of ≤20 mm or ≥26 mm.

          -  Previously diagnosed with Diabetes Mellitus and/or an HbA1c of &gt;6.5%, and with retinal
             findings consistent with diabetic retinopathy.

          -  Prior or concurrent therapies for age related macular degeneration including
             submacular surgery, subfoveal thermal laser photocoagulation (with or without
             photographic evidence), transpupillary thermotherapy (TTT), ocular photodynamic
             therapy, radiation therapy to the head or neck in the study eye.

          -  Previous posterior vitrectomy, or any surgery in the study eye within 6 months or YAG
             capsulotomy within 3 months prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis O'Shaughnessy, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Oraya Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordination Prof. Michael Stur</name>
      <address>
        <city>Wien</city>
        <zip>A-1180</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital Prague</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Hospital Prague</name>
      <address>
        <city>Prague</city>
        <zip>169 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kopfklinikum University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Augenheilkunde</name>
      <address>
        <city>Neubrandenburg</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17036</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Vita-Salute Istituto Scientifico San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>I-20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BDP 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Devon</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Wolverhampton Hospital NHS Foundation Trust</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV3 9QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.orayainc.com/clinicaltrials.asp</url>
    <description>Click here to learn about this and other studies being conducted at Oraya Therapeutics, Inc.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <results_first_submitted>November 13, 2014</results_first_submitted>
  <results_first_submitted_qc>December 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2014</results_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oraya</keyword>
  <keyword>Oraya Therapeutics, Inc.</keyword>
  <keyword>low voltage stereotactic radiotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>IRay</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Lucentis</keyword>
  <keyword>AMD</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>xray</keyword>
  <keyword>radiation</keyword>
  <keyword>x ray</keyword>
  <keyword>external beam radiation</keyword>
  <keyword>radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>16 Gy IRay</title>
          <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="P2">
          <title>24 Gy IRay</title>
          <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="P3">
          <title>Sham IRay</title>
          <description>Sham 24 or 16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>12 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>24 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>36 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>16 Gy IRay</title>
          <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="B2">
          <title>24 Gy IRay</title>
          <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="B3">
          <title>Sham IRay</title>
          <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.35" spread="7.18"/>
                    <measurement group_id="B2" value="73.77" spread="8.26"/>
                    <measurement group_id="B3" value="73.45" spread="7.14"/>
                    <measurement group_id="B4" value="73.52" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Lucentis® Injections Up To And Including Week 52</title>
        <time_frame>During the first 52 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lucentis® Injections Up To And Including Week 52</title>
          <units>Injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="2.46"/>
                    <measurement group_id="O2" value="2.44" spread="2.41"/>
                    <measurement group_id="O3" value="3.73" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Visual Acuity (VA)</title>
        <time_frame>Weeks 12, 28, 52 and 104.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Visual Acuity (VA)</title>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visual Acuity (VA) - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.91" spread="12.72"/>
                    <measurement group_id="O2" value="58.75" spread="12.79"/>
                    <measurement group_id="O3" value="59.29" spread="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in VA Week 12, n = 73, 71, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="5.68"/>
                    <measurement group_id="O2" value="1.85" spread="9.73"/>
                    <measurement group_id="O3" value="2.06" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in VA Week 28, n = 73, 73, 77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="8.25"/>
                    <measurement group_id="O2" value="2.04" spread="8.58"/>
                    <measurement group_id="O3" value="1.42" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in VA Week 52, n = 74, 72, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="8.77"/>
                    <measurement group_id="O2" value="0.40" spread="10.33"/>
                    <measurement group_id="O3" value="-0.58" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in VA Week 104, n = 68, 68, 73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.03" spread="16.45"/>
                    <measurement group_id="O2" value="-7.49" spread="16.49"/>
                    <measurement group_id="O3" value="-6.71" spread="17.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (Pct.) of Patients (Pts.) Losing &lt; 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</title>
        <time_frame>Weeks 12, 28 and 52.</time_frame>
        <population>Number of Participants Analyzed:
Week 12: n = 73, 71, 78
Week 28: n = 73, 73, 77
Week 52: n = 74, 72, 79</population>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (Pct.) of Patients (Pts.) Losing &lt; 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</title>
          <population>Number of Participants Analyzed:
Week 12: n = 73, 71, 78
Week 28: n = 73, 73, 77
Week 52: n = 74, 72, 79</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pct. of Pts. Losing &lt;15 Letters From Base. - W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pct. of Pts. Losing &lt;15 Letters From Base. - W28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pct. of Pts. Losing &lt;15 Letters From Base. - W52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (Pct.) of Patients (Pts.) Gaining ≥ 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</title>
        <time_frame>Weeks 12, 28 and 52.</time_frame>
        <population>Number of Participants Analyzed:
Week 12: n = 73, 71, 78
Week 28: n = 73, 73, 77
Week 52: n = 74, 72, 79</population>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (Pct.) of Patients (Pts.) Gaining ≥ 15 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</title>
          <population>Number of Participants Analyzed:
Week 12: n = 73, 71, 78
Week 28: n = 73, 73, 77
Week 52: n = 74, 72, 79</population>
          <units>Proportion of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pct. of Pts. Gaining &gt;=15 Letters from Base. -W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pct. of Pts. Gaining &gt;=15 Letters from Base. -W28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pct. of Pts. Gaining &gt;=15 Letters from Base. -W52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (Pct.) of Patients (Pts.) Gaining ≥ 0 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</title>
        <time_frame>Weeks 12, 28 and 52.</time_frame>
        <population>Number of Participants Analyzed:
Week 12: n = 73, 71, 78
Week 28: n = 73, 73, 77
Week 52: n = 74, 72, 79</population>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (Pct.) of Patients (Pts.) Gaining ≥ 0 Letters of Best Correct Visual Acuity (BCVA) From Baseline (Base.)</title>
          <population>Number of Participants Analyzed:
Week 12: n = 73, 71, 78
Week 28: n = 73, 73, 77
Week 52: n = 74, 72, 79</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pct. of Pts. Gaining &gt;=0 Letters From Base. - W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pct. of Pts. Gaining &gt;=0 Letters From Base. - W28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pct. of Pts. Gaining &gt;=0 Letters From Base. - W52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Mandatory Injection at Day 0 to the First PRN Injection.</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Mandatory Injection at Day 0 to the First PRN Injection.</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.29" lower_limit="12.14" upper_limit="20.29"/>
                    <measurement group_id="O2" value="16.71" lower_limit="12.57" upper_limit="26.29"/>
                    <measurement group_id="O3" value="13.14" lower_limit="12.14" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number (No.) of Lucentis® Injections (Inject.) During The First 12, 28, and 104 Weeks.</title>
        <time_frame>Week 12, 28, and 104</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number (No.) of Lucentis® Injections (Inject.) During The First 12, 28, and 104 Weeks.</title>
          <units>Number of Injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean No. of Injections - Week 12, n = 75,75,80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.70"/>
                    <measurement group_id="O2" value="0.56" spread="0.74"/>
                    <measurement group_id="O3" value="0.73" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of Injections - Week 28, n = 75,75,80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="1.35"/>
                    <measurement group_id="O2" value="1.28" spread="1.37"/>
                    <measurement group_id="O3" value="1.83" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean No. of Injections - Week 104, n=75,75,80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="3.94"/>
                    <measurement group_id="O2" value="5.37" spread="4.57"/>
                    <measurement group_id="O3" value="6.61" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Choroidal Neovascularization (CNV) as % of Lesion on Fluorescein Angiography (FA) From Baseline to Week 52</title>
        <time_frame>Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>16 Gy IRay</title>
            <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O2">
            <title>24 Gy IRay</title>
            <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
          <group group_id="O3">
            <title>Sham IRay</title>
            <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Choroidal Neovascularization (CNV) as % of Lesion on Fluorescein Angiography (FA) From Baseline to Week 52</title>
          <units>CNV as % of Lesion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.33"/>
                    <measurement group_id="O2" value="-0.18" spread="0.33"/>
                    <measurement group_id="O3" value="-0.10" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting from Baseline through week 104.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>16 Gy IRay</title>
          <description>16 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="E2">
          <title>24 Gy IRay</title>
          <description>24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
        <group group_id="E3">
          <title>Sham IRay</title>
          <description>Sham 16 or 24 Gy IRay + PRN Lucentis®
IRay: Low voltage stereotactic radiotherapy system</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Retinal Vein Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Limb operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cyst drainage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Foot operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of macular degeneration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and the Principal Investigator agree not to publish or issue a press release or authorize the publication or presentation of any Study Results without obtaining Oraya’s prior written approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Denis O'Shaugnessy, Ph.D.</name_or_title>
      <organization>Oraya Therapeutics Inc.</organization>
      <phone>917-417-3974</phone>
      <email>doshaughnessy@orayainc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

